Clinical evaluation of perhexiline maleate in patients with angina pectoris.
This paper reports a double-blind trial of a new antianginal drug, perhexiline. Fifty-five patients suffering from angina pectoris were studied for periods of 12 or 24 weeks in a cross-over comparison against a placebo in four centres in the United Kingdom and Ireland. Perhexiline was effective in most patients as judged by reducing the number of anginal attacks in 84% and the consumption of glyceryl trinitrate tablets in 64%. The major side effect, dizziness, noted in one-third of the patients, may be dose/body-weight related. Perhexiline is a valuable new agent for the treatment of patients with angina, especially those who do not respond to other antianginal agents.
D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy*; D001835:Body Weight; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008298:Maleates / Q000627:therapeutic use; D008875:Middle Aged; D005996:Nitroglycerin / Q000008:administration & dosage; D010880:Piperidines / Q000627:therapeutic use*; D010919:Placebos; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*
D008298:Maleates; D010880:Piperidines; D010919:Placebos; D014665:Vasodilator Agents; D005996:Nitroglycerin